What progress has been made in treatment of immunocompromised COVID-19 patients?

While immunocompromised patients are at very high risk of developing severe COVID 19, few of them have been enrolled in studies aimed at evaluating treatments. In the early stages of research on this disease, glucocorticoid therapy became the standard of care for patients requiring oxygen supplement...

Descripción completa

Detalles Bibliográficos
Autores principales: Ader, F., Bauer, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468055/
https://www.ncbi.nlm.nih.gov/pubmed/36108972
http://dx.doi.org/10.1016/j.idnow.2022.09.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468055/
https://www.ncbi.nlm.nih.gov/pubmed/36108972
http://dx.doi.org/10.1016/j.idnow.2022.09.009

Ejemplares similares